Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

Frontiers in Pharmacology Pub Date : 2024-11-05 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1382342

Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan

{"title":"Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.","authors":"Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan","doi":"10.3389/fphar.2024.1382342","DOIUrl":null,"url":null,"abstract":"Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.Results: The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.Conclusion: Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1382342"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573544/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1382342","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.

Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.

Results: The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.

Conclusion: Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.

查看原文本刊更多论文

评估尼妥珠单抗加吉西他滨-顺铂治疗 aUC 在中国的成本效益。

目的：从中国支付方的角度评估尼伐单抗联合吉西他滨-顺铂治疗晚期尿路上皮癌（aUC）的成本效益：采用马尔可夫模型评估经济结果，以质量调整生命年（QALYs）估算健康结果。进行了单向和概率敏感性分析，以评估不确定性对结果的影响：基础病例分析显示，Nivolumab联合吉西他滨-顺铂治疗可获得0.59个质量调整生命年，额外成本为78,780.61美元，增量成本效益比（ICER）为133,526.46美元/质量调整生命年。单向敏感性分析强调了Nivolumab的成本是关键因素，而概率敏感性分析表明，在aUC治疗中，Nivolumab联合吉西他滨-顺铂的成本效益几率为0%：结论：Nivolumab 联合吉西他滨-顺铂治疗 aUC 不具成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.80

自引率

8.90%

发文量

5163

审稿时长

14 weeks

期刊介绍： Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.